Global market access is complicated enough without the added confusion of persistent myths.
From misunderstood MDSAP requirements to overestimated CE marking reach, these assumptions can derail your expansion timeline and budget. Let’s set the record straight.
❌The myth: CE mark = instant market access across all European countries
✅ The reality: Whilst the CE mark grants access to the EU/EEA, individual countries may have additional requirements such as registration with national authorities, language-specific labelling, and local representation. Some countries require notification before placing devices on their market.
→ Country-specific requirements vary significantly across Europe
Myth #2: MDSAP replaces all individual country audits
❌ The myth: One MDSAP audit covers all participating countries automatically
✅ The reality: MDSAP has three different participation levels: Member, Official Observer, and Affiliate. Only full Members (Australia, Brazil, Canada, Japan, USA) accept MDSAP audits in lieu of their own. Official Observers (like the UK) participate but don’t yet fully recognise MDSAP audits. The programme streamlines but doesn’t eliminate country-specific requirements.
→ Understanding each country’s MDSAP status is crucial for your audit strategy
Myth #3: Mutual recognition agreements mean automatic approval
❌ The myth: If countries have a mutual recognition agreement, my certification is automatically valid
✅ The reality: Mutual recognition agreements (MRAs) facilitate the process but typically still require country-specific submissions, local representation, and compliance with national requirements. They reduce duplication, not eliminate local procedures entirely.
→ Each country maintains sovereign authority over market access
Myth #4: ISO 13485 certification is enough for most markets
❌ The myth: With ISO 13485, I’m covered for QMS requirements globally
✅ The reality: Whilst ISO 13485 is widely recognised, many countries have additional QMS requirements. Some require country-specific QMS certificates, others demand local inspections, and certain markets expect compliance with their own quality system regulations beyond ISO 13485.
→ QMS requirements layer ISO 13485 with local specifications
Myth #5: Registration timelines are predictable and consistent
❌ The myth: I can plan market entry with fixed timelines
✅ The reality: Registration durations vary dramatically – from weeks to over 12 months – depending on device classification, country workload, documentation completeness, and whether clinical data requirements are met. The same device class can face 3-month approval in one country and 18-month review in another.
→ Market-specific planning is essential, not optional
Myth #6: English labelling and IFUs work everywhere
❌ The myth: English documentation is universally accepted
✅ The reality: Most countries require labelling and instructions for use in their official language(s). Even English-speaking countries may have specific terminology or formatting requirements. Some markets mandate professional translation and certification of translated documents.
→ Language compliance is both regulatory and legal requirement
Myth #7: Once registered, I’m set indefinitely
❌ The myth: Market access approval is permanent
✅ The reality: Registration validity periods vary from 1 year to 5+ years depending on the country and device class. Renewals often require updated documentation, fee payments, and demonstration of ongoing compliance. Some markets require annual renewals regardless of device class.
→ Market access is an ongoing commitment, not a one-time achievement
Planning market entry or have questions about specific regulatory requirements? Our team provides tailored market access consulting to help you navigate the complexities with confidence. Get in touch: mike.seidenberg@eumediq.eu